Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer: exploratory analysis from KEYNOTE-119
J Pathol Clin Res. 2024 May;10(3):e12371. doi: 10.1002/2056-4538.12371.ABSTRACTThe efficacy of pembrolizumab monotherapy versus chemotherapy increased with increasing programmed death ligand 1 (PD-L1) expression, as quantified by combined positive score (CPS; PD-L1 expression on both tumour cells and immune cells) in patients with previously treated metastatic triple-negative breast cancer (mTNBC) in the phase 3 KEYNOTE-119 study. This exploratory analysis was conducted to determine whether the expression of PD-L1 on tumour cells contributes to the predictive value of PD-L1 CPS in mTNBC. PD-L1 expression in tumour samples ...
Source: Clinical Breast Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Javier Cortes Eric P Winer Oleg Lipatov Seock-Ah Im Anthony Gon çalves Eva Mu ñoz-Couselo Keun Seok Lee Peter Schmid Kenji Tamura Laura Testa Isabell Witzel Shoichiro Ohtani Stephanie Hund Karina Kulangara Vassiliki Karantza Jaime A Mejia Junshui Ma Pet Source Type: research
Maintenance pembrolizumab therapy in patients with metastatic HER2-negative breast cancer with prior response to chemotherapy
CONCLUSIONS: Pembrolizumab monotherapy achieved durable treatment responses. Patients with a high baseline T-cell clonality had prolonged disease control with pembrolizumab.PMID:38629963 | DOI:10.1158/1078-0432.CCR-23-2947 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Toshiaki Iwase Evan N Cohen Hui Gao Angela Alexander Megumi Kai Vivian Chiv Xiaoping Wang Savitri Krishnamurthy Diane Liu Yu Shen Kumiko Kida Alexandre Reuben Rachel Layman David Ramirez Debu Tripathy Stacy L Moulder Clinton Yam Vicente Valero Bora Lim Ja Source Type: research
Genomic landscape and clinical features of advanced thyroid carcinoma: a national database study in Japan
CONCLUSION: Genetic abnormalities with treatment options were found in 62.7% of advanced thyroid carcinomas. TP53 abnormality was an independent poor prognostic factor for overall survival in differentiated thyroid carcinoma. The time to treatment failure for lenvatinib was not different based on genetic profile.PMID:38630010 | DOI:10.1210/clinem/dgae271 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Soji Toda Yukihiko Hiroshima Hiroyuki Iwasaki Katsuhiko Masudo Source Type: research
Efficacy of pembrolizumab and biomarker analysis in patients with WGS-based intermediate to high tumor mutational load: results from the Drug Rediscovery Protocol
CONCLUSION: While in cohort A pembrolizumab lacked activity, cohort B and cohort C met the study's primary endpoint. Further research is warranted to refine selection of patients with tumors harboring lower TMLs and may benefit from a focus on innate immunity.PMID:38630551 | DOI:10.1158/1078-0432.CCR-24-0011 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Birgit S Geurts Laurien J Zeverijn Lindsay V M Leek Jade M van Berge Henegouwen Louisa R Hoes Hanneke van der Wijngaart Vincent van der Noort Joris van de Haar Annemiek van Ommen-Nijhof Marleen Kok Paul Roepman Anne M L Jansen Wendy W J de Leng Maja J A d Source Type: research
NTRK-rearranged spindle cell neoplasm: Initial observation of imaging appearance and clinicopathologic correlation
CONCLUSION: NTRK-rearranged neoplasms may occur as enhancing masses with linear hypointense signal foci on MRI and FDG avid metastases on PET. Pulmonary metastases were frequent in our study. Initial treatment response is observed in most patients.PMID:38631176 | DOI:10.1016/j.clinimag.2024.110134 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Matthew Spano Cecilia Davis-Hayes Meera Hameed Ryma Benayed Sinchun Hwang Source Type: research
A Study on the Retrospective Reinterpretation of BRCA1 and BRCA2 Variants
CONCLUSIONS: We determined the class and proportion of reclassified BRCA variants. In conclusion, reviews are required to provide clinical guidance, such as determining treatment direction and preventive measures in the future.PMID:38623660 | DOI:10.7754/Clin.Lab.2023.230911 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 16, 2024 Category: Cancer & Oncology Authors: Jin Ju Kim Dong Ja Kim Eon Jeong Nam Kyung Eun Song Ji Yeon Ham Yu Kyung Kim Nan Young Lee Source Type: research
Highlights in metastatic breast cancer from the 2023 San Antonio Breast Cancer Symposium
Clin Adv Hematol Oncol. 2024 Feb;22 Suppl 1(1):1-16.NO ABSTRACTPMID:38625028 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 16, 2024 Category: Cancer & Oncology Source Type: research
Highlights in metastatic breast cancer from the 2023 San Antonio Breast Cancer Symposium: commentary
Clin Adv Hematol Oncol. 2024 Feb;22 Suppl 1(1):13-15.NO ABSTRACTPMID:38625029 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 16, 2024 Category: Cancer & Oncology Authors: Aditya Bardia Source Type: research
Development of an Ultrasound-based Nomogram for Predicting Pathologic Complete Response and Axillary Response in Node-Positive Patients with Triple- Negative Breast Cancer
CONCLUSION: The nomogram showed promising predictive performance for predicting breast and ALN pCR in patients with TNBCs.PMID:38627192 | DOI:10.1016/j.clbc.2024.03.012 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 16, 2024 Category: Cancer & Oncology Authors: Manqi Zhang Hailing Zha Jiazhen Pan Xiaoan Liu Min Zong Liwen Du Yu Du Source Type: research
Existing Psychiatric Diagnoses Among Breast Cancer Patients Interact with Outcomes After Autologous and Implant-Based Bilateral Breast Reconstruction: A Propensity Score Matched Analysis
CONCLUSION: Existing psychiatric diagnoses were shown to strongly predict and modulate risk of adverse postoperative outcomes depending on modality of reconstruction.PMID:38627193 | DOI:10.1016/j.clbc.2024.03.010 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 16, 2024 Category: Cancer & Oncology Authors: George S Corpuz Dylan K Kim Isaac E Kim Christine H Rohde Source Type: research
Imaging for local recurrence of breast cancer
CONCLUSION: In breast cancer survivors, MRI might improve the early detection of ILRR and CBC in both HBOC and nHBOC patients.PMID:38627285 | DOI:10.1007/s00432-024-05709-2 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 16, 2024 Category: Cancer & Oncology Authors: T Schlaiss L Bott S-L Herbert C Bartmann M Kiesel J Salmen S T Sauer S A Christner B Petritsch J-P Grunz A Woeckel S L öb J Diessner Source Type: research
CCAAT enhancer binding protein delta activates vesicle associated membrane protein 3 transcription to enhance chemoresistance and extracellular PD-L1 expression in triple-negative breast cancer
CONCLUSION: This study provides novel evidence that CEBPD plays a key role in enhancing PTX resistance in TNBC cells across various subtypes through VAMP3-mediated autophagy activation. Additionally, the CEBPD/VAMP3 axis also increases extracellular PD-L1 level, delivered by cancer cell-derived EVs, to suppress CD8+ T cell-mediated anti-tumor immune response. These significant observations may provide new insights into the treatment of TNBC, suggesting CEBPD and VAMP3 as promising targets to overcome treatment resistance.PMID:38627816 | DOI:10.1186/s13046-024-03041-8 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 16, 2024 Category: Cancer & Oncology Authors: Yan Zhao Yangyang Yu Xiangmin Li Ayao Guo Source Type: research
A Study on the Retrospective Reinterpretation of BRCA1 and BRCA2 Variants
CONCLUSIONS: We determined the class and proportion of reclassified BRCA variants. In conclusion, reviews are required to provide clinical guidance, such as determining treatment direction and preventive measures in the future.PMID:38623660 | DOI:10.7754/Clin.Lab.2023.230911 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 16, 2024 Category: Cancer & Oncology Authors: Jin Ju Kim Dong Ja Kim Eon Jeong Nam Kyung Eun Song Ji Yeon Ham Yu Kyung Kim Nan Young Lee Source Type: research
Highlights in metastatic breast cancer from the 2023 San Antonio Breast Cancer Symposium
Clin Adv Hematol Oncol. 2024 Feb;22 Suppl 1(1):1-16.NO ABSTRACTPMID:38625028 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 16, 2024 Category: Cancer & Oncology Source Type: research
Highlights in metastatic breast cancer from the 2023 San Antonio Breast Cancer Symposium: commentary
Clin Adv Hematol Oncol. 2024 Feb;22 Suppl 1(1):13-15.NO ABSTRACTPMID:38625029 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 16, 2024 Category: Cancer & Oncology Authors: Aditya Bardia Source Type: research
